Renal cell carcinoma is characterized by a lack of specific clinical signs that allow the diagnosis at an early stage (1) . Therefore, a high proportion of patients will have metastasis at the time of first diagnosis and cannot be cured, since there is no effective therapy for metastatic renal cancer. Radiotherapy, chemotherapy, or hormonotherapy have little or no effect in this disease (1) , although immunomodulating agents, cytokines, or differentiating agents such as retinoids have shown antitumor activity in a small proportion of patients with metastatic renal cancer (2) (3) (4) . Because of its poor prognosis, there is a need for novel and more selective drugs that are able to interfere with targets directly involved in the process of renal cancer development and progression.
Experimental and clinical studies have provided evidence for a transforming growth factor-␣ (TGF-␣)-epidermal growth factor receptor (EGFR)-mediated autocrine growth stimulatory pathway in a variety of human cancers, including renal cancer (5) . Overexpression of TGF-␣ and EGFR has been associated with poor prognosis and metastatic spreading (6) (7) (8) . Thus, the use of anti-EGFR-blocking monoclonal antibodies (MAbs), of recombinant proteins containing TGF-␣ or epidermal growth factor (EGF) fused to toxins, or of EGFR-specific tyrosinekinase inhibitors has been proposed as a potential therapeutic modality (9) (10) (11) (12) (13) (14) (15) (16) . Several blocking anti-EGFR MAbs that inhibit the in vitro and in vivo growth of human cancer cell lines overexpressing TGF-␣ and EGFR have been obtained (17, 18) . Among these, MAb 528 and MAb 225 are two mouse MAbs that have been extensively characterized for their biologic and preclinical properties and represent the first series of anti-EGFR blocking agents that have entered clinical evaluation in cancer patients (9, 10, 19, 20) . To allow repeated administrations of these antibodies without the production of human anti-mouse antibodies in cancer patients, a chimeric human-mouse MAb 225 (MAb C225), that contains the human immunoglobulin G 1 (IgG 1 ) constant region, has recently been developed and purified for clinical use and is in early clinical trials (21) (22) (23) (24) . Protein kinase A (PKA) is an intracellular enzyme involved in the controlling of cell growth and differentiation. Mammalian cells produce two isoforms, type I (PKAI) and type II (PKAII), with identical catalytic subunits but different cyclic adenosine monophosphate (cAMP)-binding regulatory subunits (termed RI in PKAI and RII in PKAII) (25) . PKAI mediates mitogenic signals upon receptor ligation of different growth factors, including EGF and TGF-␣ (26) (27) (28) (29) . PKAI is also directly involved in cell proliferation and neoplastic transformation (30, 31) and is required for the G 1 -S transition of the cell cycle. PKAI overexpression has been detected in a majority of human cancers and correlates with less favorable clinicopathologic features and poor prognosis in patients with ovarian and breast cancers (25, 32, 33) . In contrast, PKAII is expressed in normal tissues and seems to be involved in cellular differentiation (25, 32) . The ratio of PKAI levels to PKAII levels in renal cell carcinomas is almost twice that of normal renal cortex (34) . For this reason, the inhibition of PKAI activity or synthesis has been an appropriate target for the development of therapeutic agents. The selective down-regulation of PKAI activity by the cAMP analog 8-chlorocAMP (8-Cl-cAMP) inhibits growth of a wide variety of cancer cell types in vitro and in vivo and is accompanied by decreased expression of different oncogenes and growth factor genes (35) (36) (37) (38) . In addition, 8-Cl-cAMP can be safely administered to cancer patients (39) , justifying further clinical trials. A genetic approach to inhibiting PKAI expression has been recently developed by the use of phosphorothioate antisense oligonucleotides targeting the synthesis of PKAI regulatory subunit RI␣. These oligonucleotides inhibit growth of several human cancer cell lines in vitro and in vivo (40) (41) (42) . However, in vivo toxicity studies conducted with phosphorothioate oligonucleotides have shown nonsequence-specific side effects, which may be due to their polyanionic structure (43) . Therefore, to improve the therapeutic potential of the antisense approach, novel antisense oligonucleotides with mixed backbone structure (MBOs) containing both methylphosphonate-and PS-modified residues have been synthesized. The MBOs have better pharmacokinetic and toxicity profiles in vivo (44) . We have recently shown that HYB 190, an anti-RI␣ MBO, inhibits the growth of human colon, ovary, and breast cancer cell lines at submicromolar concentrations and has a cooperative growth inhibitory activity with different classes of cytotoxic drugs, including taxanes, platinumderived agents, and topoisomerase II-selective drugs (45) .
Previously, we provided evidence for a structural and functional basis for neoplastic transformation involving a TGF-␣-EGFR autocrine pathway and increased PKAI expression and activation (26, (29) (30) (31) . We also characterized a cooperative antiproliferative effect of anti-EGFR MAbs with the PKAI inhibitor 8-Cl-cAMP on growth of human cancer cell lines in vitro and in vivo (46, 47) . In the current study, we evaluated the potential antiproliferative and antitumor activity of the anti-EGFR MAb C225 and the RI␣ HYB 190 antisense MBO separately and in combination on four human renal cancer cell lines.
Materials and Methods
MAbs and MBOs. The biochemical and biological characteristics of MAb C225, a human-mouse chimeric anti-EGFR IgG 1 class MAb, have been previously described (21) . MAb C225 was provided by H. Waksal (ImClone Systems, New York, NY). Synthesis of antisense 18-mer MBOs targeted to the 5Ј-terminal 8-13 codons of human RI␣ regulatory subunit messenger RNA for PKA (45) was previously described (44) . The PKAI antisense oligonucleotide, designated HYB 190, had the following sequence: 5Ј-GCGTGCCTCCTCACTGGC-3Ј. A control PKAI antisense oligonucleotide containing four mismatched nucleotides was designated HYB 239. The mismatched nucleotides in HYB 239 are underlined: 5Ј-GCATGCATCCGCACAGGC-3Ј. Both HYB 190 and HYB 239 contain phosphorothioate-and methylphosphonate-internucleotide linkages. These linkages are represented in standard upper case letters (phosphorothioate) and by boldface upper case letters (methylphosphonate) for the flanking nucleotides. The identity of each oligonucleotide was confirmed by 31 P nuclear magnetic resonance. Chemical purity of each MBO was determined by capillary gel electrophoresis, hybridization melting temperature, and A 269 /mass ratio (44) .
Cell lines. Human renal cancer 769-P, ACHN, A498, and SW839 cells were obtained from the American Type Culture Collection (Manassas, VA). Cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal bovine serum, 20 mM HEPES, pH 7.4, penicillin (100 IU/mL), streptomycin (100 g/mL), and 4 mM glutamine (ICN, Irvine, CA) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
Protein blot analysis. Samples of total cellular protein (50 g) were fractionated through 7.5% or 12% sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose filters, incubated with specific MAbs, followed by incubation with horseradish-peroxidase antiserum (Bio-Rad Laboratories, Milan, Italy). Immunoreactive proteins were visualized by enhanced chemiluminescence (Amersham Italia, Milan, Italy), as described previously (31) . The following specific antibodies were used: anti-human EGFR mouse MAb (Transduction Laboratories, Lexington, KY); anti-human RI␣ mouse MAb (Transduction Laboratories). Lysates from MCF-10A cells overexpressing RI␣ (MCF-10A RI␣) were used as positive controls for RI␣ expression (26) .
Growth in soft agar assay. Cells (10 4 cells/well) were suspended in 0.5 mL of 0.3% Difco Noble agar (Difco Laboratories, Inc., Detroit, MI) supplemented with complete culture medium (see cell lines above). This suspension was layered over 0.5 mL of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson, Lincoln Park, NJ) and treated with different concentrations of MAb C225 and/or oligonucleotide HYB 190 or oligonucleotide HYB 239 every 2 days, for a total of 4 days. After 12 days, the cells were stained with nitro blue tetrazolium (Sigma Chemical Co., St. Louis, MO) and colonies larger than 0.05 mm were counted as previously described (46) . Apoptosis assay. To evaluate the potential induction of apoptosis, 10 5 cells were plated in complete medium (see cell lines above) in 60-mm tissue culture dishes (Becton Dickinson, Lincoln Park, NJ) and treated every day for a total of 3 days with different concentrations of MAb C225 and/or oligonucleotide HYB 190. At the indicated time points, both adherent and detached cells were harvested. Flow cytometric analysis of apoptotic cell death was performed on cell pellet fixed in 70% ethanol, washed in phosphate-buffered saline and mixed with ribonuclease (Sigma Chemical Co.) and propidium iodide (Sigma Chemical Co.) solution as previously reported (48) . DNA content was analyzed by a FACScan flow-cytometer (Becton Dickinson, San Jose, CA) coupled with a HewlettPackard computer. The percentage of apoptotic cells was calculated by gating the hypodiploid region on the DNA content histogram using the LYSYS software (Becton Dickinson) as previously reported (48) .
ACHN xenografts in nude mice. Five-to 6-week-old female BALB/ cAnNCrlBR athymic (nu+/nu+) mice were purchased from Charles River Laboratories (Milan, Italy). The research protocol was approved and the mice were maintained in accordance with the institutional guidelines of the University of Naples Animal Care and Use Committee. Mice were acclimated to the University of Naples Medical School Animal Facility for 1 week prior to being injected with cancer cells. Mice were injected subcutaneously with 10 7 ACHN cells that were resuspended in 200 L of Matrigel (Collaborative Biomedical Products, Bedford, MA). After 10 days, when well-established xenografts were detectable (tumor size approximately 0.30 cm 3 ), each group of 10 mice received one of the following treatments: 1) intraperitoneal injections of MAb C225 (0.25 mg/dose) twice weekly for 3 weeks; 2) intraperitoneal injections of oligonucleotide HYB 190 (200 g/dose) for 5 days per week for 3 weeks; or 3) a combination of MAb C225 and oligonucleotide HYB 190 given with the above-described schedule. Tumor size was calculated using the formula /6 × larger diameter × (smaller diameter) 2 as previously reported (47) . Statistical analysis. Student's t test was used to evaluate the statistical significance of the results. All P values represent two-sided tests of statistical significance. All analyses were performed with the BMDPNew System statistical package version 1.0 for Microsoft Windows (BMDP Statistical Software, Los Angeles, CA).
Results
To determine whether the EGFR and the RI␣ subunit of PKAI were expressed by renal cancer cell lines, protein blots were performed using cell extracts produced from 769-P, ACHN, A498, and SW839 cells. As shown in Fig. 1 , immunoreactive EGFR and RI␣ bands were detected in all four cell lines, suggesting that these cell lines could be suitable models for examining the effect(s) of agents that block the expression or function of the EGFR and/or the RI␣ subunit of PKAI. There- (Fig. 2, A) . The IC 50 (i.e., concentration that causes 50% inhibition of growth) for MAb C225 was between 0.8 and 1.8 g/mL. Similarly, oligo- . Samples of total cellular protein (50 g) were fractionated through 7.5% or 12% sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose filters, and incubated with specific anti-EGFR or anti-RI␣ monoclonal antibodies, followed by horseradish-peroxidase antiserum. Immunoreactive proteins were visualized by enhanced chemiluminescence (see ''Materials and Methods''). nucleotide HYB 190 inhibited growth in a dose-dependent manner (Fig. 2, B) .
In contrast, the control oligonucleotide, HYB 239, at doses up to 2.5 M, showed only 5%-15% growth inhibition in the soft agar assay among all of the cell lines tested (Fig. 2, C) .
To determine whether the growth inhibitory effect of oligonucleotide HYB 190 correlated with a reduction in RI␣ protein levels, we performed protein blots on total cell extracts prepared from ACHN cells treated with oligonucleotide HYB 190 or oligonucleotide HYB 239. Compared with untreated ACHN cells, RI␣ levels were substantially unchanged, even in cells treated with a higher dose of the control oligonucleotide HYB 239 (1 M). However, dose-dependent inhibition of RI␣ expression was seen when ACHN cells were treated with oligonucleotide HYB 190 (Fig. 3) .
To determine whether a combination of MAb C225 and oligonucleotide HYB 190 could enhance the antiproliferative effect compared with either agent alone, 769-P cells and ACHN cells were treated with different combinations of the two agents. As shown in Fig. 4 , a supraadditive effect was observed with both renal cell lines at all doses of MAb C225 and oligonucleotide HYB 190 examined. When lower doses of these agents were used, the growth inhibitory effect was cooperative for either cell line. For example, in 769-P cells treatment with HYB 190, 0.1 M, determined less than 3% growth inhibition, whereas treatment with MAb C225 (0.25 and 0.5 g/mL) caused 6% and 35% growth inhibition, respectively. Treatment with oligonucleotide HYB 190 (0.1 M), plus MAb C225, at a concentration of either 0.25 or 0.5 g/mL, produced 37% and 62% inhibition of colony formation in soft agar, respectively. For these treatment combinations, the cooperativity quotient, defined as the ratio of the net percent growth-inhibition effect by the agents in combination to the sum of the percent growth inhibition achieved by each agent (35, 45) . See ''Materials and Methods'' for details on cell culture conditions. Samples of total cellular proteins (50 g) were fractionated through 12% sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose filters, and incubated with specific anti-RI␣ monoclonal antibody, followed by horseradishperoxidase antiserum. Immunoreactive proteins were visualized by enhanced chemiluminescence (see ''Materials and Methods''). g/mL) did not induce apoptosis in 769-P cells, although it increased apoptotic cell death in ACHN cells from 6% of cells to 21% of cells after 4 days (P ‫ס‬ .05) and 8 days (P ‫ס‬ .05) of incubation. Treatment with both agents increased the percentage of 769-P cells entering programmed cell death from 5% to 21% and 24% at day 4 (P ‫ס‬ .004) and day 8 (P ‫ס‬ .004), respectively (Fig. 5, A) . A combination of anti-EGFR MAb and oligonucleotide HYB 190 induced apoptosis in 36%-40% of all ACHN cells compared with untreated cells (6%) (P ‫ס‬ .002) or to MAb C225-treated cells (21%) (P ‫ס‬ .01) (Fig. 5, B) . These results suggest that the cooperative antiproliferative activity of oligonucleotide HYB 190 and MAb C225 involves induction of programmed cell death. This cooperative induction of apoptosis was specific for the combination of the anti-EGFR blocking antibody and the anti-RI␣ antisense oligonucleotide, because ACHN (B) renal cancer cells. Cells were treated with the indicated concentrations of the two agents for 3 days. Flow cytometric analysis of DNA fragmentation was performed after 4 ( ) and 8 () days after the beginning of treatment (see ''Materials and Methods''). Data represent the average (+ standard error) of triplicate determinations. Student's t test was used to compare apoptotic cell death among different treatment groups at days 4 and 8. In panel A, no statistically significant differences in the percent of apoptotic cells were observed between MAb C225-treated 769-P cells and control, nontreated 769-P cells or between oligonucleotide HYB 190-treated 769-P cells and control, nontreated 769-P cells either at day 4 or day 8. A statistically significant difference in the percent of apoptotic cells was observed between 769-P cells co-treated with MAb C225 and oligonucleotide HYB 190 and control, nontreated 796-P cells (two-sided P ‫ס‬ .004 at day 4; two-sided P ‫ס‬ .004 at day 8). In panel B, no statistically significant differences in the percent of apoptotic cells were observed between oligonucleotide HYB 190-treated ACHN cells and control, nontreated ACHN cells either at day 4 or at day 8. A statistically significant difference in the percent of apoptotic cells was observed between MAb C225-treated ACHN cells and control nontreated ACHN cells (two-sided P ‫ס‬ .05 at day 4; two-sided P ‫ס‬ .05 at day 8), between MAb C225 and oligonucleotide HYB 190 co-treated ACHN cells and control, untreated ACHN cells (two-sided P ‫ס‬ .002 at day 4; two-sided P ‫ס‬ .002 at day 8), and between ACHN cells co-treated with MAb C225 and oligonucleotide HYB 190 and ACHN cells treated with only MAb C225 (two-sided P ‫ס‬ .01 at day 4; two-sided P ‫ס‬ .01 at day 8). of the experiment), the average ACHN cell tumor was reduced to 17% of its original size (day 10 of the experiment) (Fig. 6) . In addition, two of 10 mice in the MAb C225 plus oligonucleotide HYB 190 treated group were tumor free from day 28 through day 42 of the experiment. In contrast, tumor size had increased by 377% in the untreated control group and by 198% and 208% in the groups treated with MAb C225 or oligonucleotide HYB 190 alone, respectively (Fig. 6 ). Both MAb C225 and oligonucleotide HYB 190 treatments alone or in combination were well tolerated by mice: no weight loss or other signs of acute or delayed toxicity were observed.
Discussion
A major approach to treating cancer is based on the use of cytotoxic drugs acting on intracellular targets that are generally common to both cancer and normal cells. Improved treatment efficacy has been obtained by combining two or more drugs and/or modifying their dosage and schedule of administration. However, several human cancer types are still relatively insensitive or have become resistant to cytotoxic drugs. For example, chemotherapeutic agents have little or no effect on advancedstage renal cell carcinoma (1) .
As an alternative cancer therapy, the use of biologic agents acting via different mechanisms may have a direct antitumor effect or may modulate the host immune response during the course of this disease. Examples of such agents are retinoids, the interferons, and interleukin 2. Each of these agents have entered clinical evaluation for the treatment of advanced renal cancer or as adjuvant treatment in selected groups of high-risk patients following radical surgery (2) (3) (4) . As an extension of this approach, inhibition of growth factor receptor activation and/or intracellular mitogenic signal transduction pathways may represent a promising strategy for the development of novel anticancer treatments (50) . In this respect, blocking EGFR function is clinically relevant because this growth factor receptor is frequently overexpressed and activated in renal cancer cells (5) (6) (7) 51) . Moreover, increased PKAI activity and protein levels have been seen in human cancer cells where it is known that a TGF-␣/EGFR autocrine pathway is active (26, 30, 31) , among them primary human renal cancer cells (34) . A role for PKAI in EGFR-mediated signaling is supported by evidence that PKAI acts downstream to the EGFR (29) . Thus, PKAI is a good candidate for targeted inhibition by therapeutic agents.
We recently showed that a combined blockade of EGFR tyrosine kinase activity using anti-EGFR MAbs and of PKAI serine/threonine kinase using the cAMP analog 8-Cl-cAMP interferes with cancer cell intracellular signaling at the level of two different biochemical pathways. This combination of agents produced a cooperative potentiation of antitumor activity over that achieved by either agent alone (46, 47) .
In the current study, we determined whether double blockade of PKAI and EGFR could be obtained in human renal cancer cells using a combination of a humanized anti-EGFR MAb (MAb C225) and a RI␣ antisense oligonucleotide (HYB 190). Our goal was to develop a model biologic therapy for treatment of human renal cancer that could be translated and explored in a clinical setting. In this respect, phase I clinical studies have shown that repeated administration of MAb C225 can be given to patients with different forms of advanced cancer at doses that produce receptor-saturating levels in the blood, but without toxicity (22) . Phase II clinical studies of MAb C225 alone or in combination with cytotoxic drugs, such as cisplatin or doxorubicin, are currently ongoing (23, 24) . Oligonucleotide HYB 190 is the prototype of a novel series of modified oligonucleotides with mixed backbone structure designed to target PKAI (43) (44) (45) . HYB 190 contains methylphosphonate linkages in the middle of the nucleotide sequence. The presence of these centrally modified oligonucleotides have significantly reduced side effects in vivo compared with phosphorothioate-modified oligonucleotides (44) . PKAI MBOs are entering clinical evaluation in phase I studies in cancer patients.
The results of the current study show that MAb C225 and oligonucleotide HYB190 inhibit cell growth of several human renal cancer cell lines by blocking EGFR function and inhibiting PKAI expression in a dose-dependent manner. Furthermore, a marked increase in both their in vitro and in vivo antiproliferative activities was observed when the agents were used in combination. In fact, blockade of EGFR function and inhibtion of PKAI expression caused an antiproliferative effect that was not simply additive. This effect was specific for the combination of MAb C225 and oligonucleotide HYB 190, because oligonucleotide HYB 239, a four-base mismatched molecule, did not affect renal cancer cell growth when used either alone or in concert with the anti-EGFR MAb C225. A plausible mechanism by which oligonucleotide HYB 190 could exert its antiproliferative effect with MAb C225 is by inducing programmed cell death. In fact, we observed increased numbers of apoptotic 769-P cells and ACHN cells when each was treated with MAb C225 and oligonucleotide HYB 190 in combination. It is likely that the combined blockade of the EGFR and PKAI signal transduction pathways, which are required for cells to traverse from G 1 to S phases of the cell cycle, would render cancer cells more susceptible to apoptosis.
We also evaluated whether the cooperative growth inhibitory effect of MAb C225 and oligonucleotide HYB 190 observed in vitro could also be observed in vivo. We found that a 3-week treatment of nude mice bearing established ACHN cell xenografts with MAb C225 or with HYB 190 had a cytostatic growth inhibitory effect with a reduction in the tumor growth rate compared with untreated controls. A dramatic effect on tumor growth was seen in mice treated with both agents for the same period and the same dosage as single agent-treated mice: the induced tumors regressed, with no evidence of any tumor in two of 10 mice. The combined treatment with MAb C225 and oligonucleotide HYB 190 was well tolerated by the mice without signs of acute or delayed toxicity, suggesting that a longer treatment protocol could be given.
In terms of nonspecific toxicity, it should be noted that oligonucleotide HYB 190 does not specifically target mouse RI␣. Therefore, we cannot rule out the possibility of toxicity due to inhibition of endogenous RI␣ in mice treated with a specific anti-mouse RI␣ antisense oligonucleotide. However, we have recently shown that 8-Cl-cAMP, a cytotoxic compound known to inhibit both mouse PKAI activity and human PKAI activity, can be administered as a single agent or in combination with MAb C225 to nude mice bearing human GEO colon cancer xenografts for 5-10 weeks with no signs of toxicity [(47); our unpublished results].
Cancer cell growth can be inhibited by anti-EGFR MAbs or antisense RI␣ in concert with different classes of cytotoxic drugs, including taxanes, platinum derivatives, and topoisomerase II inhibitors (45, 52, 53) . In this study, we showed that both anti-EGFR MAbs and antisense RI␣ MBOs were cooperative inhibitors of renal cancer cell growth. Because anti-EGFR MAbs and antisense RI␣ MBOs mediate their effects by different mechanisms, it is unlikely that they would also share overlapping side effects or to antagonize the activity of cytotoxic drugs (45, 47, 52, 53) . Therefore, a combination of MAb C225 and oligonucleotide HYB 190 following chemotherapy is an approach worthy of additional investigation in patients with renal cancer.
